

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/256074203>

Investigation of Known Genetic Risk Factors for Primary Open Angle Glaucoma in Two Populations of African Ancestry

Article in *Investigative ophthalmology & visual science* · August 2013

DOI: 10.1167/iovs.13-12779 · Source: PubMed

CITATIONS

37

READS

75

19 authors, including:



Yutao Liu

Medical College of Georgia, Augusta University, Augusta, US

146 PUBLICATIONS 2,201 CITATIONS

SEE PROFILE



Michael A Hauser

Duke University

249 PUBLICATIONS 10,763 CITATIONS

SEE PROFILE



Stephen Akafo

University of Ghana

14 PUBLICATIONS 342 CITATIONS

SEE PROFILE



Douglas E Gaasterland

The EMMES Corporation

157 PUBLICATIONS 5,080 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Glaucoma Case Report [View project](#)



Homocysteine and AMD [View project](#)

Investigation of Known Genetic Risk Factors for Primary Open Angle Glaucoma in Two Populations of African Ancestry

Yutao Liu^{1,2*}, Michael A Hauser^{1,2*}, Stephen K. Akafo¹⁰, Xuejun Qin¹, Shiroh Miura¹, Jason R. Gibson¹, Joshua Wheeler¹, Douglas E. Gaasterland⁴, Pratap Challa², Leon W. Herndon², ICAARE-Glaucoma, Robert Ritch⁵, Sayoko E. Moroi³, Louis R. Pasquale⁸, Christopher A. Girkin⁶, Donald L. Budenz⁷, Janey L. Wiggs⁸, Julia E. Richards^{3,9}, Allison E. Ashley-Koch¹, R. Rand Allingham²

The International Consortium of African Ancestry REsearch in Glaucoma (ICAARE–Glaucoma) is led by Dr. Michael A. Hauser and Dr. R. Rand Allingham, and includes the following investigators: Stephen Akafo, Adeyinka Ashaye, Allison E. Ashley-Koch, Rupert Bourne, Donald L. Budenz, Pratap Challa, John H. Fingert, Douglas E. Gaasterland, Christopher A. Girkin, Fielding Hejtmancik, Leon Herndon, Rachel Kuchtey, Paul R. Lichter, Yutao Liu, Sayoko E. Moroi, Barbara Nemesure, Louis R. Pasquale, Julia E. Richards, Robert Ritch, Janey L. Wiggs, Susan Williams,

¹Department of Medicine, ²Department of Ophthalmology, Duke University Medical Center, Durham, NC; ³Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI; ⁴Eye Doctors of Washington DC, Washington DC; ⁵Einhorn Clinical Research Center, Department of Ophthalmology, New York Eye & Ear Infirmary, New York, NY; ⁶Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL; ⁷Department of Ophthalmology, University of North Carolina, Chapel Hill, NC; ⁸Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA; ⁹Department of Epidemiology, University of Michigan, Ann Arbor, MI; ¹⁰Unit of Ophthalmology, Department of Surgery, University of Ghana Medical School, Accra, Ghana.

*Contributed equally.

Corresponding Author:

R. Rand Allingham

Duke University Eye Center

Durham, NC 27710

Phone: (919) 684-2975

E-mail: allin002@mc.duke.edu

Abstract Word Count: 245

Main Text Word Count: 2,555

Abstract

Purpose Multiple genes have been associated with primary open angle glaucoma (POAG) in Caucasian populations. We now examine the association of these loci in populations of African ancestry, populations at particularly high risk for POAG.

Methods We genotyped DNA samples from two populations: African American (1150 cases and 999 controls) and Ghana, West Africa (483 cases and 593 controls). Our analysis included 57 single nucleotide polymorphisms (SNPs) in five loci previously associated with POAG at the genome-wide level, including *CDKN2B-AS1*, *TMCO1*, *CAV1/CAV2*, chromosome 8q22 intergenic region, and *SIX1/SIX6* were studied. We evaluated association in the full datasets, as well as subgroups with normal pressure glaucoma (NPG, maximum IOP \leq 21 mmHg) and high pressure glaucoma (HPG, IOP > 21 mmHg).

Results In African Americans, we identified an association of rs10120688 in the *CDKN2B-AS1* region with POAG ($p = 0.0020$). Several other SNPs were nominally associated, but did not survive correction for multiple testing. In the subgroup analyses, significant associations were identified for rs10965245 ($p=0.0005$) in the *CDKN2B-AS1* region with HPG and rs11849906 in the *SIX1/SIX6* region with NPG ($p=0.006$). No significant association was identified with any loci in the Ghanaian samples.

Conclusions POAG genetic susceptibility alleles associated in Caucasians appear to play a greatly reduced role in populations of African ancestry. Thus the major genetic components of POAG of African origin remain to be identified. This finding underscores the critical need to pursue large-scale genome wide association studies in this understudied, yet disproportionately affected population.

Introduction

Glaucoma is the second leading cause of blindness in the world¹. Primary open angle glaucoma (POAG) is the most common type and is inherited as a complex trait²⁻⁴. POAG is characterized by progressive retinal ganglion cell death, optic nerve head excavation, and visual field loss. POAG disproportionately affects individuals of African ancestry^{5, 6}, and is the most common cause of permanent blindness in African Americans⁷. The risk of POAG in persons over age 40 is four- to five-fold higher in African Americans (4-5%) than in age-matched Caucasians (1%)^{5, 8-10}. It is also more severe, with a 10-fold higher risk of blindness from glaucoma in African Americans^{1, 11}. POAG is even more common and severe in continental African populations¹²⁻¹⁶. In a major population-based study in Ghana, West Africa, POAG was diagnosed in 6% of those over the age of 40, which is one of the highest global prevalence rates ever reported¹⁴. In studies conducted in eye clinics serving populations of African ancestry rates of blindness in one or both eyes have been observed in excess of 40%^{13, 17-20}.

Genetics has been shown to play an important role in the pathogenesis of POAG^{2-4, 21, 22}. Previous linkage-based studies have identified several genes with varying contribution to glaucoma, including myocilin, *CYP1B1*, optineurin, and *WDR36*²³⁻²⁶. It has also been reported that DNA copy number changes in *TBK1* and *GALC* gene contribute to POAG pathogenesis²⁷,²⁸. Recently, genome-wide association studies (GWAS) of POAG in Iceland, Australia, Japan, and the U.S. have successfully identified and confirmed genetic associations that are significant at the genome-wide level with multiple genes involved in the pathogenesis of POAG, including: *CAV1/CAV2*, *CDKN2B-AS1*, *TMCO1*, *SIX1/SIX6*, and an intergenic region on chromosome 8q22²⁹⁻³². Multiple studies have confirmed or replicated these genetic associations in populations from Europe, the US, Japan, and Barbados³³⁻³⁶. However, these loci have not been examined in populations of African ancestry including African Americans and continental Africans. This study was designed to fill this significant gap.

We have assembled the **International Consortium of African Ancestry REsearch in Glaucoma (ICAARE-Glaucoma)** with glaucoma investigators from the US and Africa (including Ghana, Nigeria, and South Africa). In this study, we used a haplotype-tagging approach to examine genetic associations in more than 3200 African American and Ghanaian (West African) glaucoma cases and controls from the ICAARE-Glaucoma.

Materials and Methods

Study Sample and Phenotype Description

This study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participating individuals. The research was reviewed and approved by the Institutional Review Board from all participating institutions, including Duke University Medical Center (Durham, NC), the Massachusetts Eye and Ear Infirmary (Boston, MA), the University of Michigan (Ann Arbor, MI), New York Eye & Ear Infirmary (New York, NY), the University of Alabama at Birmingham (Birmingham, AL), and, for Ghanaian subjects, Noguchi Memorial Institute of Medical Research of the College of Health Sciences, University of Ghana in Accra.

Subjects with POAG were unrelated and met the following inclusion criteria³⁷ : 1) glaucomatous optic neuropathy in at least one eye; 2) visual field loss consistent with optic nerve damage in at least one eye. Glaucomatous optic neuropathy was defined as a cup-to-disc ratio greater than 0.7 or focal loss of the nerve fiber layer resulting in a notch in the neuroretinal rim, associated with a glaucomatous visual field defect. Visual fields were performed using standard automated perimetry or frequency doubling test (FDT) ¹. IOP was recorded but not used as an inclusion criterion. The exclusion criteria for POAG subjects included the diagnosis or history of any secondary glaucoma, history of ocular trauma, or significant use of systemic or ocular glucocorticoids. Medical records for all POAG cases and control subjects were reviewed by professionally trained glaucoma specialists. The examined control subjects were unrelated and met the following criteria: 1) no known first-degree relative with glaucoma; 2) IOP less than

21 mmHg in both eyes without treatment; and 3) no evidence of glaucomatous optic neuropathy in either eye. POAG cases were further stratified into high pressure glaucoma (HPG) or normal pressure glaucoma (NPG) based on maximum recorded IOP > 21 mmHg or < 22 mmHg, respectively.

DNA genotyping and Association Analysis

Genomic DNA was extracted from peripheral blood by standard techniques (Gentra, Minneapolis, MN, USA). HaploView version 4.2 was used to design the tagging SNPs of *CAV1/CAV2*, *CDKN2B-AS1*, *TMCO1*, and *SIX1/SIX6* in African (YRI) samples, using genotype data from the HapMap project (www.hapmap.org) with $r^2 > 0.6$ and minor allele frequency (MAF) > 0.05¹⁴. A total of 50 tagging SNPs were selected to cover the linkage disequilibrium (LD) blocks of the selected candidate regions (Supplemental Figure 1). We also included seven additional SNPs (rs284489 on chromosome 8, rs1063192, rs4977756, rs10116277, and rs4977574 in the *CDKN2B-AS1* region, rs33912345 and rs10483727 in the *SIX1/SIX6* region) that were strongly associated with POAG in Caucasians^{32,38}. TaqMan allelic discrimination assays were employed for genotyping these 57 SNPs by use of Assays-On-Demand products with the ViiA7 Realtime PCR system with 384-well block according to the standard protocols from the manufacturer (Applied Biosystems, Foster City, CA, USA). All 57 SNPs were genotyped in 1076 Ghanaians. Due to technical issues, 50 SNPs were genotyped on the whole set of 2149 African Americans. Seven SNPs (rs10800149 and rs7518099 in *TMCO1* region, rs2151280, rs1547705, rs10738607, and rs10811658 in *CDKN2B-AS1* region, and rs3759688 in *SIX1/SIX6* region) were genotyped in 1593 African Americans. For quality-control (QC) purposes, two CEPH (the Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France) standards were included in each 96-well plate, and samples from two individuals were duplicated across all plates, with the laboratory technicians masked to their identities. Analysis of genotypes required matching QC genotypes within and across plates and

at least 95% genotyping efficiency.

Analysis of Hardy-Weinberg equilibrium (HWE) was performed separately for cases and controls from the two populations using GDA software.¹⁵ Within each population, genotype frequencies of POAG cases and controls were compared by logistic regression with adjustment for age and sex using SAS software (SAS Institute Inc., Cary, NC). SNP genotypes were coded according to a log-additive model, in which the relative risk for carriers of two variant (minor) alleles, compared to the reference group (homozygous wild-type), was assumed to be the square of the relative risk for carriers of one variant. We also performed the association analysis based on classification of NPG or HPG. In order to correct for testing multiple SNPs in each genomic region, we calculated the effective number of independent marker loci (MeffLi) to control the experiment-wise level of significance and the false discovery rate based on the method reported by Li and Ji³⁹. The values of MeffLi are 6.000 for *TMCO*, 9.106 for *CAV1/CAV2*, 19.146 for *CDKN2B-AS*, and 7.000 for *SIX1/SIX6*. The experiment-wide significance threshold required to limit type 1 error rate to 5% is 0.0085 for *TMCO*, 0.0056 for *CAV1/CAV2*, 0.0027 for *CDKN2B-AS1*, and 0.0073 for *SIX1/SIX6*. Because there is only one SNP in the chromosome 8 locus, the significance for p-value cut-off is 0.05. Power calculations were performed with QUANTO software using previously described methods, assuming a population prevalence of 5% and a log-additive risk model.^{37, 40} To address the genetic heterogeneity between the African American and Ghanaian populations, we conducted a formal meta-analysis of the SNPs with the African American and Ghanaian datasets with PLINK⁴¹.

Results

The ICAARE-Glaucoma dataset at the time of this study consisted of 2,149 African Americans and 1,076 Ghanaians (West African). The African American cohort contained 1,150 POAG cases and 999 fully ophthalmically-examined controls. The Ghanaian cohort contained 483 POAG cases and 593 examined controls. Phenotypic information is provided in **Table 1**.

Although elevated IOP was not required for the diagnosis of POAG, the Ghanaian POAG cases essentially all demonstrated elevated IOP at examination so NPG subset analysis was not performed.

All SNPs passed rigorous quality control and genotyping efficiency criteria (> 95% with all the samples). All were in Hardy-Weinberg equilibrium (HWE) in both cases and controls from both African Americans and Ghanaians ($p > 0.01$), except for two SNPs with minor deviations (rs1063192 in African American controls (HWE $p = 0.007$), rs4977574 in African American cases (HWE $p = 0.003$). SNP rs1063192 in the *CDKN2B-AS1* region was monomorphic in Ghanaian controls and rare in Ghanaian POAG cases (a minor allele frequency of 0.002 for the C allele that is protective in the Caucasian POAG.)

In the full African American case/control dataset, we observed a significant association of SNP rs10120688 in the *CDKN2B-AS1* region with POAG risk ($p = 0.0020$; OR [odds ratio] (95%CI) = 1.21 (1.07-1.37)). Several other SNPs reached nominal significance ($p < 0.05$), including rs7518099 in the *TMCO1* region, rs1052990 and rs4236601 in the *CAV1/CAV2* region, rs7049105, rs16905597, rs16905599, rs10811658, and rs10965245 in the *CDKN2B-AS1* region (Table 2). However, these associations did not survive correction for multiple testing. In the Ghanaian population, nominal associations were noted for several SNPs, including rs3807986, rs3815412, and rs8713 in the *CAV1/CAV2* region. However, none of these associations remained significant after correction for multiple testing in each genomic region. The meta-analysis with these two populations identified five nominally significant SNPs ($p < 0.05$), including rs7518099 and rs2814471 in *TMCO1*, rs4236601 in *CAV1/CAV2* and rs10120688 and rs16905597 in *CDKN2B-AS1*, that did not survive correction for multiple testing.

Next, we stratified the African American cases by IOP history into normal pressure glaucoma (NPG) and high pressure glaucoma (HPG) for association analysis using logistic regression. In the HPG subgroup, we identified significant association with SNP rs10965245

($p=0.0005$; OR=0.73 (0.61-0.87)) in the *CDKN2B-AS1* region. Nominal associations that did not survive correction for multiple testing were noted for several SNPs including rs4236601 in the *CAV1/CAV2* region, rs7049105, rs10120688, rs16905597, rs16905599, rs10965235, and rs17761446 in the *CDKN2B-AS1* region (Table 2).

In the NPG subgroup, we found significant association with SNP rs11849906 in the *SIX1/SIX6* regions ($p=0.006$; OR=0.53 (0.34-0.83)). Nominal associations that did not survive correction for multiple testing were observed with several SNPs including rs7518099 and rs2814471 in the *TMCO1* region, rs4236601 in the *CAV1/CAV2* region, rs10120688 and rs4977756 in the *CDKN2B-AS1* region (Table 2). Additional details of the association with all 57 SNPs in these five genomic regions are presented in Supplementary Table 1. The Ghanaian POAG cases were almost all classified as HPG so stratification by IOP was not performed.

In order to determine the statistical power of these datasets to detect association with these genetic loci we selected an OR of 1.5 and 1.35 obtained from reports on the genetic associations in these regions. Reported ORs were 1.68 for *TMCO1*³², 1.4-1.5 for *CDKN2B-AS1*^{29, 32}, 1.32 for *SIX1/SIX6*^{29, 35}, and 1.36 for *CAV1/CAV2* variants.^{33, 42} Statistical power to detect association with these genomic loci was calculated using Quanto software⁴⁰. Assuming population risk $\alpha=0.05$ and allele frequency of 0.10, our African American dataset has 98.9% power for OR of 1.5 and 87.2% power for OR of 1.35. The Ghanaian dataset has 85% power for OR of 1.5 and 59% power for OR of 1.35. In summary, our African American and Ghanaian datasets were well-powered to detect associations in these regions.

Discussion

Our study represents the largest association study of glaucoma to date in populations of African ancestry. We replicated the association of POAG with the *CDKN2B-AS1* locus in the African Americans first reported in populations of European ancestry^{6, 29, 32, 34, 35, 43, 44}. After stratification for IOP this association remained significant in the HPG subgroup. We also found

significant association of the *SIX1/SIX6* locus in African American cases in the NPG subgroup. Interestingly, we did not observe significant association with any of the previously reported genes and loci in POAG cases from the West African population of Ghana. This may be due to the relatively limited sample size of the Ghanaian dataset.

Several studies have reported the association of *CDKN2B-AS1* SNPs, and upon stratification by IOP history, this association is restricted to the NPG but not the HPG subpopulation^{29, 32, 38, 43-46}. In African Americans, we see significant association with *CDKN2B-AS1* SNPs in the full dataset and in the HPG subgroup. This difference in pattern may be due to the small sample size of our NPG dataset (280 cases and 999 controls), which reflects the smaller proportion of African Americans with NPG. Cao et al reported the association of rs1063192 in this region in the Afro-Caribbean populations of Barbados, West Indies⁴⁷. Consistent with our other findings, we do not observe this association in either African Americans or Ghanaians. The protective C allele of this SNP is rare in the Ghanaian population (MAF=0.002 in cases vs. 0 in controls). In addition, the mean IOP of POAG cases in the Barbados dataset was 22.5mmHg, significantly lower than the 26.2mmHg observed in our African American cases. These facts may contribute to the lack of association with the *CDKN2B-AS1* locus in Ghanaians and African Americans.

We have also identified a significant association of rs11849906 in the *SIX1/SIX6* region in African American NPG subgroup ($p=0.006$; $OR=0.53\pm 0.34-0.83$). This SNP is monomorphic in the Caucasian and Asian populations from the International HapMap Project (<http://hapmap.ncbi.nlm.nih.gov>) and is polymorphic only in populations of African ancestry, including African Americans and Africans in Nigeria, Kenya. Additional studies in populations of African ancestry are required to replicate this finding.

The lack of association with *TMCO1*, *CAV1/CAV2*, or the chromosome 8q22 intergenic region may be secondary to the limited sample size or perhaps due to smaller effect sizes in populations of African ancestry compared with Caucasians. The lack of associations with

specific variants previously identified in Caucasian populations may be explained by the rarity of those alleles in African populations. Several associated SNPs common in Caucasians were rare in the Ghanaians, including rs10483727 and rs33912345 in the *SIX1/SIX6* region, rs10116277 and rs1063192 in the *CDKN2B-AS1* region, potentially limiting the effect that these alleles could have on POAG risk.

Admixture in the African Americans and genetic heterogeneity between the African American and Ghanaian populations may also influence our association findings. Our meta-analysis of these loci with the African American and Ghanaian data sets indicates that five SNPs were nominally significant ($p < 0.05$) in the meta-analysis (rs7518099 and rs2814471 in *TMCO1*, rs4236601 in *CAV1/CAV2* and rs10120688 and rs16905597 in *CDKN2B-AS1*). Interestingly, for the SNPs in *TMCO1* and *CAV1/CAV2*, the odds ratios and risk alleles were consistent between populations, while, for *CDKN2B-AS1*, the odds ratios and risk allele were opposite in the two populations (Table 2 and Supplemental Table 1). This suggests that some of the risk for POAG in the African American population may be explained by Caucasian admixture (*CDKN2B-AS1*), while other POAG risk factors may be driven by African-derived risk alleles.

Mutations in myocilin and optineurin have been documented in POAG cases. Previous studies^{14, 48-52} found that, despite the high prevalence of POAG in the populations of African ancestry, the mutations in these two genes play a relatively limited role. The increased prevalence of glaucoma in the African populations is not due to a higher prevalence of myocilin mutations. In this study, approximately 573 African American and 100 Ghanaian POAG cases have been screened for myocilin mutations^{49, 50}. Patients carrying any known mutations were excluded in our analysis. Given the relatively rare frequency of myocilin mutations in these African populations, we expect that the association results will not be affected by the lack of myocilin screening in the remaining POAG cases. In addition, several studies have confirmed the lack of significant association of common variants in myocilin with POAG in the Caucasians

^{38, 53}. Collectively, these results suggest that other currently unknown genetic risk factors contribute to POAG in these African populations.

Our findings suggest that genetic associations for POAG found in Caucasian populations appear to play a much smaller role in populations of African ancestry, leaving a large portion of genetic architecture of African POAG to be determined. This is not surprising since Africa in general, and Sub Saharan Africa in particular, contains the anthropologically oldest and most heterogeneous populations on Earth who have experienced environmental conditions that have historically contributed unique selection pressures. In the long term, multiple genome-wide association studies of POAG in populations of African descent will be required to not only validate the known glaucoma loci, but also to identify novel variants and loci in specific populations of African ancestry that contribute to POAG pathogenesis and related blindness.

Acknowledgement

We are grateful to the study participants, without whom this work would not have been possible. We also want to thank the research infrastructure of the Duke Center for Human Genetics including the Molecular Genomics Core facility, DNA Bank and Tissue Repository, and PEDIGENE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262-267.
2. Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. *The Journal of clinical investigation* 2010;120:3064-3072.
3. Fingert JH. Primary open-angle glaucoma genes. *Eye (Lond)* 2011;25:587-595.
4. Liu Y, Allingham RR. Molecular genetics in glaucoma. *Experimental eye research* 2011;93:331-339.
5. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA : the journal of the American Medical Association* 1991;266:369-374.
6. Ramdas WD, van Koolwijk LM, Ikram MK, et al. A genome-wide association study of optic disc parameters. *PLoS genetics* 2010;6:e1000978.
7. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. *Ophthalmology* 1992;99:1499-1504.
8. Leske MC, Wu SY, Honkanen R, et al. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. *Ophthalmology* 2007;114:1058-1064.
9. Racette L, Wilson MR, Zangwill LM, Weinreb RN, Sample PA. Primary open-angle glaucoma in blacks: a review. *Survey of ophthalmology* 2003;48:295-313.
10. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. *Arch Ophthalmol* 2004;122:532-538.
11. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. *Arch Ophthalmol* 2004;122:477-485.
12. Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, et al. Prevalence of glaucoma in an African population. *Eye (Lond)* 2004;18:491-497.
13. Kyari F, Abdull MM, Bastawrous A, Gilbert CE, Faal H. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors. *Middle East African journal of ophthalmology* 2013;20:111-125.
14. Budenz DL, Barton K, Whiteside-de Vos J, et al. Prevalence of glaucoma in an urban west african population: the tema eye survey. *JAMA ophthalmology* 2013;131:651-658.
15. Budenz DL, Bandi JR, Barton K, et al. Blindness and visual impairment in an urban West African population: the Tema Eye Survey. *Ophthalmology* 2012;119:1744-1753.
16. Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga BB. Prevalence of glaucoma in a rural East African population. *Investigative ophthalmology & visual science* 2000;41:40-48.
17. Nair KS, Hmani-Aifa M, Ali Z, et al. Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice. *Nature genetics* 2011;43:579-584.
18. Lu J, Lal A, Merriman B, Nelson S, Riggins G. A comparison of gene expression profiles produced by SAGE, long SAGE, and oligonucleotide chips. *Genomics* 2004;84:631-636.
19. Wilson MR, Kosoko O, Cowan CL, Jr., et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. *American journal of ophthalmology* 2002;134:399-405.
20. Herndon LW, Challa P, Ababio-Danso B, et al. Survey of glaucoma in an eye clinic in Ghana, West Africa. *Journal of glaucoma* 2002;11:421-425.
21. Allingham RR, Liu Y, Rhee DJ. The genetics of primary open-angle glaucoma: a review. *Experimental eye research* 2009;88:837-844.
22. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. *The New England journal of medicine* 2009;360:1113-1124.

23. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science* 2002;295:1077-1079.
24. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. *Science* 1997;275:668-670.
25. Monemi S, Spaeth G, DaSilva A, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. *Human molecular genetics* 2005;14:725-733.
26. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. *Human molecular genetics* 1997;6:641-647.
27. Fingert JH, Robin AL, Stone JL, et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. *Human molecular genetics* 2011;20:2482-2494.
28. Liu Y, Gibson J, Wheeler J, et al. GALC deletions increase the risk of primary open-angle glaucoma: the role of Mendelian variants in complex disease. *PloS one* 2011;6:e27134.
29. Lachke SA, Alkuraya FS, Kneeland SC, et al. Mutations in the RNA granule component TDRD7 cause cataract and glaucoma. *Science* 2011;331:1571-1576.
30. Takamoto M, Kaburaki T, Mabuchi A, et al. Common variants on chromosome 9p21 are associated with normal tension glaucoma. *PloS one* 2012;7:e40107.
31. Osman W, Low SK, Takahashi A, Kubo M, Nakamura Y. A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. *Human molecular genetics* 2012;21:2836-2842.
32. Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. *Nature genetics* 2011.
33. Wiggs JL, Kang JH, Yaspan BL, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. *Human molecular genetics* 2011;20:4707-4713.
34. Abu-Amero KK, Kondkar AA, Mousa A, Osman EA, Al-Obeidan SA. Lack of association of SNP rs4236601 near CAV1 and CAV2 with POAG in a Saudi cohort. *Molecular vision* 2012;18:1960-1965.
35. Fan BJ, Wang DY, Pasquale LR, Haines JL, Wiggs JL. Genetic variants associated with optic nerve vertical cup-to-disc ratio are risk factors for primary open angle glaucoma in a US Caucasian population. *Investigative ophthalmology & visual science* 2011;52:1788-1792.
36. Gibson J, Griffiths H, De Salvo G, et al. Genome-wide association study of primary open angle glaucoma risk and quantitative traits. *Molecular vision* 2012;18:1083-1092.
37. Liu Y, Schmidt S, Qin X, et al. Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations. *Investigative ophthalmology & visual science* 2008;49:3465-3468.
38. Wiggs JL, Yaspan BL, Hauser MA, et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. *PLoS genetics* 2012;8:e1002654.
39. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. *Heredity* 2005;95:221-227.
40. Gauderman WJ. Candidate gene association analysis for a quantitative trait, using parent-offspring trios. *Genetic epidemiology* 2003;25:327-338.
41. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *AmJHumGenet* 2007;81:559-575.
42. Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. *Nature genetics* 2010;42:906-909.
43. Boon K, Osorio EC, Greenhut SF, et al. An anatomy of normal and malignant gene expression. *Proceedings of the National Academy of Sciences of the United States of America* 2002;99:11287-11292.

44. Kastner P, Grondona JM, Mark M, et al. Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. *Cell* 1994;78:987-1003.
45. Mabuchi F, Sakurada Y, Kashiwagi K, Yamagata Z, Iijima H, Tsukahara S. Association between genetic variants associated with vertical cup-to-disc ratio and phenotypic features of primary open-angle glaucoma. *Ophthalmology* 2012;119:1819-1825.
46. Nakano M, Ikeda Y, Tokuda Y, et al. Common variants in CDKN2B-AS1 associated with optic-nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese. *PLoS one* 2012;7:e33389.
47. Cao D, Jiao X, Liu X, et al. CDKN2B polymorphism is associated with primary open-angle glaucoma (POAG) in the Afro-Caribbean population of Barbados, West Indies. *PLoS one* 2012;7:e39278.
48. Liu Y, Akafo S, Santiago-Turla C, et al. Optineurin coding variants in Ghanaian patients with primary open-angle glaucoma. *Molecular vision* 2008;14:2367-2372.
49. Challa P, Herndon LW, Hauser MA, et al. Prevalence of myocilin mutations in adults with primary open-angle glaucoma in Ghana, West Africa. *Journal of glaucoma* 2002;11:416-420.
50. Liu W, Liu Y, Challa P, et al. Low prevalence of myocilin mutations in an African American population with primary open-angle glaucoma. *Molecular vision* 2012;18:2241-2246.
51. Fingert JH, Heon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. *Human molecular genetics* 1999;8:899-905.
52. Whigham BT, Williams SE, Liu Y, et al. Myocilin mutations in black South Africans with POAG. *Molecular vision* 2011;17:1064-1069.
53. Ramdas WD, van Koolwijk LM, Cree AJ, et al. Clinical implications of old and new genes for open-angle glaucoma. *Ophthalmology* 2011;118:2389-2397.

Table 1. Clinical characteristics of individuals in ICAARE-Glaucoma (International Consortium of African Ancestry REsearch in Glaucoma).

Affection status	N	% Female	Age (years)	Maximal IOP (mmHg)
African American Total	2,149	51.9	58.1±13.4	22.2±9.0
African American Cases	1150	49.5	57.0±13.0	26.2±8.8
African American HPG	870	48.7	56.0±12.7	30.0±7.4
African American NPG	280	49.8	58.9±13.3	16.9±3.6
African American Controls	999	54.6	59.4±13.8	15.2±3.1
Ghanaians Total	1,076	51.3	63.3±11.8	31.2±12.6
Ghanaian Cases	483	43.9	63.4±12.4	35.1±11.6
Ghanaian Controls	593	57.3	63.3±9.6	18.4±5.6

Age: age at diagnosis for cases and age of examination for controls. HPG: high pressure glaucoma. NPG: normal pressure glaucoma; IOP: intraocular pressure.

Table 2. The genetic association of 57 SNPs with POAG in the ICAARE-Glaucoma samples of African Americans and Ghanaians (West Africans) using logistic regression with additive model.





Genomic Region	SNP	Allele	African American (n=1150 case/999 control)		AA HPG (n=870 case/999 control)		AA NPG (n=280 case/999 control)		Ghanaian (n=483 case/593 control)	
			P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)
<i>TMCO1</i>	rs10800149	A	0.66	1.04 (0.89-1.21)	0.74	0.97 (0.82-1.15)	0.09	1.21 (0.97-1.51)	0.10	1.19 (0.97-1.46)
<i>TMCO1</i>	rs10800150	C	0.49	0.96 (0.85-1.08)	0.74	0.98 (0.86-1.11)	0.29	0.90 (0.75-1.09)	0.24	0.90 (0.76-1.07)
<i>TMCO1</i>	rs4656461	C	0.74	1.02 (0.89-1.18)	0.82	1.02 (0.87-1.19)	0.62	1.06 (0.85-1.32)	0.19	1.14 (0.94-1.40)
<i>TMCO1</i>	rs1913845	C	0.74	1.03 (0.88-1.20)	0.40	1.08 (0.91-1.27)	0.31	0.89 (0.71-1.12)	0.76	0.97 (0.78-1.20)
<i>TMCO1</i>	rs12059327	C	0.71	0.97 (0.80-1.16)	0.93	1.01 (0.83-1.23)	0.28	0.85 (0.63-1.15)	0.22	1.17 (0.91-1.51)
<i>TMCO1</i>	rs6426940	C	0.94	1.00 (0.89-1.13)	0.98	1.00 (0.88-1.14)	0.92	1.01 (0.84-1.22)	0.31	0.91 (0.77-1.09)
<i>TMCO1</i>	rs7518099	C	0.048	1.27 (1.00-1.62)	0.12	1.23 (0.95-1.59)	0.05	1.39 (0.99-1.93)	0.11	1.29 (0.94-1.75)
<i>TMCO1</i>	rs2814471	C	0.27	1.11 (0.93-1.32)	0.80	1.03 (0.85-1.24)	0.019	1.37 (1.05-1.77)	0.76	1.04 (0.81-1.34)
<i>CAV1/CAV2</i>	rs8940	C	0.051	0.86 (0.74-1.00)	0.08	0.86 (0.73-1.02)	0.15	0.84 (0.66-1.06)	0.10	0.83 (0.67-1.04)
<i>CAV1/CAV2</i>	rs1052990	A	0.029	0.87 (0.77-0.99)	0.06	0.88 (0.77-1.00)	0.08	0.85 (0.70-1.02)	0.11	0.87 (0.73-1.03)
<i>CAV1/CAV2</i>	rs6466578	C	0.23	0.91 (0.78-1.06)	0.52	0.95 (0.80-1.12)	0.08	0.80 (0.62-1.03)	0.19	0.86 (0.70-1.07)
<i>CAV1/CAV2</i>	rs3919515	C	0.41	0.95 (0.84-1.08)	0.44	0.95 (0.83-1.09)	0.59	0.95 (0.78-1.15)	0.56	0.95 (0.79-1.13)
<i>CAV1/CAV2</i>	rs10227696	A	0.13	1.13 (0.97-1.31)	0.20	1.11 (0.94-1.32)	0.18	1.17 (0.93-1.49)	0.09	1.21 (0.97-1.51)
<i>CAV1/CAV2</i>	rs4236601	A	0.020	1.16 (1.02-1.31)	0.050	1.14 (1.00-1.31)	0.05	1.21 (1.00-1.47)	0.06	1.19 (0.99-1.42)
<i>CAV1/CAV2</i>	rs917664	A	0.72	1.02 (0.91-1.16)	0.75	1.02 (0.90-1.16)	0.79	1.03 (0.85-1.25)	0.98	1.00 (0.84-1.19)
<i>CAV1/CAV2</i>	rs3779512	A	0.43	1.05 (0.93-1.20)	0.28	1.08 (0.94-1.24)	0.90	0.99 (0.81-1.21)	0.74	1.03 (0.86-1.24)
<i>CAV1/CAV2</i>	rs3807986	C	0.97	1.00 (0.88-1.13)	0.93	1.01 (0.88-1.15)	0.84	0.98 (0.81-1.19)	0.015	0.80 (0.66-0.96)
<i>CAV1/CAV2</i>	rs3807989	C	0.97	1.00 (0.88-1.13)	0.56	0.96 (0.84-1.10)	0.28	1.12 (0.92-1.36)	0.35	0.91 (0.76-1.10)
<i>CAV1/CAV2</i>	rs3779514	A	0.69	1.03 (0.89-1.19)	0.41	1.07 (0.92-1.24)	0.47	0.92 (0.73-1.16)	0.84	0.98 (0.80-1.20)
<i>CAV1/CAV2</i>	rs3815412	A	0.51	1.04 (0.92-1.18)	0.63	1.03 (0.90-1.18)	0.54	1.06 (0.88-1.29)	0.03	0.82 (0.69-0.98)
<i>CAV1/CAV2</i>	rs8713	A	0.85	1.01 (0.89-1.16)	0.89	1.01 (0.87-1.17)	0.79	1.03 (0.83-1.27)	0.04	0.82 (0.68-0.99)
<i>Chr 8q22</i>	rs284489	C	0.69	0.98 (0.86-1.10)	0.92	0.99 (0.87-1.13)	0.44	0.93 (0.77-1.12)	0.66	1.04 (0.86-1.27)
<i>CDKN2B-AS1</i>	rs2069422	G	0.96	1.01 (0.82-1.23)	0.86	0.98 (0.79-1.22)	0.57	1.09 (0.80-1.49)	0.75	0.95 (0.71-1.28)
<i>CDKN2B-AS1</i>	rs7049105	A	0.009	0.84 (0.73-0.96)	0.013	0.83 (0.72-0.96)	0.12	0.85 (0.69-1.05)	0.75	1.03 (0.85-1.25)
<i>CDKN2B-AS1</i>	rs2151280	A	0.19	1.11 (0.95-1.29)	0.38	1.08 (0.91-1.27)	0.11	1.19 (0.96-1.48)	0.25	0.89 (0.73-1.08)
<i>CDKN2B-AS1</i>	rs7851706	C	0.26	1.11 (0.92-1.34)	0.24	1.13 (0.92-1.38)	0.66	1.07 (0.80-1.43)	0.06	0.80 (0.64-1.01)
<i>CDKN2B-AS1</i>	rs10120688	A	0.0020	1.21 (1.07-1.37)	0.012	1.18 (1.04-1.35)	0.004	1.32 (1.09-1.60)	0.10	0.86 (0.72-1.03)

<i>CDKN2B-AS1</i>	rs16905597	A	0.010	0.78 (0.64-0.94)	0.006	0.74 (0.60-0.92)	0.38	0.88 (0.66-1.18)	0.57	1.07 (0.85-1.36)
<i>CDKN2B-AS1</i>	rs16905599	C	0.04	0.86 (0.75-1.00)	0.04	0.85 (0.73-0.99)	0.33	0.90 (0.72-1.12)	0.28	1.12 (0.92-1.36)
<i>CDKN2B-AS1</i>	rs16923583	A	0.47	0.94 (0.80-1.11)	0.44	0.93 (0.78-1.11)	0.71	0.95 (0.73-1.24)	0.94	1.01 (0.81-1.25)
<i>CDKN2B-AS1</i>	rs1547705	A	0.43	1.07 (0.91-1.27)	0.33	1.10 (0.91-1.31)	0.97	1.01 (0.79-1.28)	0.89	1.01 (0.84-1.23)
<i>CDKN2B-AS1</i>	rs1537370	C	0.06	0.88 (0.77-1.00)	0.11	0.89 (0.77-1.03)	0.09	0.84 (0.68-1.03)	0.24	1.12 (0.93-1.36)
<i>CDKN2B-AS1</i>	rs10738607	C	0.32	0.92 (0.78-1.09)	0.16	0.88 (0.73-1.05)	0.82	1.03 (0.81-1.30)	0.95	0.99 (0.80-1.23)
<i>CDKN2B-AS1</i>	rs10965235	A	0.06	1.13 (1.00-1.27)	0.03	1.16 (1.01-1.32)	0.70	1.04 (0.86-1.25)	0.43	0.93 (0.79-1.11)
<i>CDKN2B-AS1</i>	rs4990722	G	0.55	1.05 (0.89-1.25)	0.65	1.04 (0.87-1.25)	0.41	1.12 (0.85-1.47)	0.79	0.97 (0.79-1.20)
<i>CDKN2B-AS1</i>	rs17761446	G	0.08	0.79 (0.60-1.03)	0.05	0.74 (0.55-1.00)	0.76	0.94 (0.63-1.41)	0.86	1.04 (0.70-1.53)
<i>CDKN2B-AS1</i>	rs1333049	C	0.10	0.89 (0.78-1.02)	0.07	0.87 (0.75-1.01)	0.78	0.97 (0.78-1.20)	0.68	1.05 (0.84-1.31)
<i>CDKN2B-AS1</i>	rs1333050	C	0.37	1.07 (0.92-1.24)	0.43	1.07 (0.91-1.26)	0.53	1.08 (0.85-1.36)	0.10	1.28 (0.95-1.73)
<i>CDKN2B-AS1</i>	rs10811658	A	0.04	1.17 (1.01-1.35)	0.07	1.16 (0.99-1.35)	0.08	1.21 (0.98-1.49)	0.48	1.07 (0.90-1.27)
<i>CDKN2B-AS1</i>	rs12347779	C	0.97	1.00 (0.78-1.27)	0.89	1.02 (0.79-1.32)	0.73	0.94 (0.65-1.35)	0.28	0.82 (0.57-1.18)
<i>CDKN2B-AS1</i>	rs10965245	A	0.006	0.80 (0.68-0.94)	0.0005	0.73 (0.61-0.87)	0.97	1.00 (0.78-1.27)	0.38	1.10 (0.89-1.35)
<i>CDKN2B-AS1</i>	rs2383208	A	0.24	0.91 (0.78-1.06)	0.42	0.94 (0.79-1.10)	0.18	0.85 (0.67-1.08)	0.47	1.09 (0.87-1.35)
<i>CDKN2B-AS1</i>	rs1063192	C	0.15	0.85 (0.67-1.06)	0.39	0.90 (0.70-1.15)	0.06	0.68 (0.46-1.01)	0.98	N/A
<i>CDKN2B-AS1</i>	rs4977756	C	0.16	0.91 (0.81-1.04)	0.41	0.95 (0.83-1.08)	0.04	0.82 (0.67-1.00)	0.44	1.07 (0.90-1.29)
<i>CDKN2B-AS1</i>	rs10116277	G	0.88	0.99 (0.81-1.20)	0.89	1.02 (0.82-1.26)	0.43	0.88 (0.64-1.21)	0.23	1.82 (0.68-4.85)
<i>CDKN2B-AS1</i>	rs4977574	A	0.48	1.05 (0.91-1.22)	0.41	1.07 (0.91-1.26)	0.99	1.00 (0.80-1.26)	0.48	1.10 (0.85-1.41)
<i>SIX1/SIX6</i>	rs2350890	C	0.31	1.07 (0.94-1.20)	0.42	1.06 (0.93-1.21)	0.36	1.09 (0.90-1.32)	0.65	1.04 (0.87-1.24)
<i>SIX1/SIX6</i>	rs4901977	A	0.99	1.00 (0.88-1.13)	0.79	0.98 (0.86-1.12)	0.67	1.04 (0.86-1.26)	0.28	1.10 (0.92-1.32)
<i>SIX1/SIX6</i>	rs8012339	A	0.56	0.95 (0.82-1.12)	0.31	0.92 (0.77-1.09)	0.64	1.06 (0.83-1.36)	0.69	0.96 (0.78-1.17)
<i>SIX1/SIX6</i>	rs1266416	C	0.50	0.96 (0.85-1.08)	0.74	0.98 (0.86-1.12)	0.24	0.90 (0.74-1.08)	0.14	1.14 (0.96-1.35)
<i>SIX1/SIX6</i>	rs3759688	A	0.88	1.01 (0.86-1.20)	0.97	1.00 (0.83-1.20)	0.63	1.06 (0.83-1.35)	0.86	0.98 (0.82-1.18)
<i>SIX1/SIX6</i>	rs11849906	G	0.43	0.91 (0.72-1.15)	0.77	1.04 (0.81-1.32)	0.006	0.53 (0.34-0.83)	0.18	1.23 (0.91-1.67)
<i>SIX1/SIX6</i>	rs10148202	A	0.13	0.88 (0.74-1.04)	0.18	0.88 (0.74-1.06)	0.24	0.85 (0.65-1.12)	0.72	1.04 (0.84-1.30)
<i>SIX1/SIX6</i>	rs7156317	A	0.73	1.02 (0.90-1.16)	0.61	1.04 (0.90-1.19)	0.87	0.98 (0.81-1.20)	0.52	1.06 (0.89-1.26)
<i>SIX1/SIX6</i>	rs7146104	A	0.17	1.24 (0.91-1.68)	0.23	1.22 (0.88-1.69)	0.25	1.32 (0.82-2.11)	0.70	0.93 (0.66-1.32)
<i>SIX1/SIX6</i>	rs10483727	C	0.67	0.96 (0.78-1.18)	0.97	0.99 (0.77-1.28)	0.66	0.92 (0.64-1.32)	0.76	1.13 (0.52-2.44)
<i>SIX1/SIX6</i>	rs33912345	A	0.25	0.88 (0.71-1.10)	0.91	0.99 (0.77-1.27)	0.57	0.90 (0.62-1.30)	0.93	0.96 (0.42-2.23)

SNP: single nucleotide polymorphism; POAG: primary open-angle glaucoma; ICAARE-Glaucoma: International Consortium of African Ancestry REsearch in Glaucoma; HPG: high pressure glaucoma; NPG: normal pressure glaucoma; AA: African American; P:

p value from the logistic regression using additive model with the justification of age and gender; OR: odds ratio; CI: confidence interval.

Supplemental Figure 1. Fifty seven tagging and previously reported SNPs were selected to cover the reported five genomic regions, including *TMCO1* (panel A), *CAV1/CAV2* (panel B), chromosome 8q22 intergenic region (panel C), *CDKN2B-AS1* (panel D), and *SIX1/SIX6* (panel E), in the African population (YRI). These tagging SNPs were selected using HaploView software with $r^2 > 0.6$ and MAF > 0.05. TaqMan allelic discrimination assays were employed for genotyping these 57 SNPs by use of Assays-On-Demand products with the ViiA7 Realtime PCR system with 384-well block according to the standard protocols from the manufacturer (Applied Biosystems, Foster City, CA, USA).



Supplemental Table 1. The genetic association of all 57 genotyped SNPs with POAG in the ICAARE-Glaucoma samples of African Americans and Ghanaians (West Africans).

Genomic Regions	SNP	Allele	African American (n=1150 case/999 control)				African American HPG (n=870 case/ 999 control)				African American NPG (n=280 case/999 control)				Ghanaian (n=483 case/593 control)			
			FU	FA	P	OR	FU	FA	P	OR	FU	FA	P	OR	FU	FA	P	OR
<i>TMCO1</i>	rs10800149	A	25.4	26.1	0.66	1.04 (0.89-1.21)	25.4	24.8	0.74	0.97 (0.82-1.15)	25.4	29.2	0.09	1.21 (0.97-1.51)	19.1	22.1	0.10	1.19 (0.97-1.46)
<i>TMCO1</i>	rs10800150	C	42.7	41.8	0.49	0.96 (0.85-1.08)	42.7	42.3	0.74	0.98 (0.86-1.11)	42.7	40.1	0.29	0.90 (0.75-1.09)	47.0	44.7	0.24	0.90 (0.76-1.07)
<i>TMCO1</i>	rs4656461	C	22.6	23.3	0.74	1.02 (0.89-1.18)	22.6	23.2	0.82	1.02 (0.87-1.19)	22.6	23.7	0.62	1.06 (0.85-1.32)	22.6	25.6	0.19	1.14 (0.94-1.40)
<i>TMCO1</i>	rs1913845	C	81.7	82.1	0.74	1.03 (0.88-1.20)	81.7	82.9	0.40	1.08 (0.91-1.27)	81.7	79.7	0.31	0.89 (0.71-1.12)	81.4	81.0	0.76	0.97 (0.78-1.20)
<i>TMCO1</i>	rs12059327	C	12.9	12.6	0.71	0.97 (0.80-1.16)	12.9	13.1	0.93	1.01 (0.83-1.23)	12.9	11.2	0.28	0.85 (0.63-1.15)	13.1	15.1	0.22	1.17 (0.91-1.51)
<i>TMCO1</i>	rs6426940	C	42.4	42.3	0.94	1.00 (0.89-1.13)	42.4	42.1	0.98	1.00 (0.88-1.14)	42.4	42.6	0.92	1.01 (0.84-1.22)	40.5	38.2	0.31	0.91 (0.77-1.09)
<i>TMCO1</i>	rs7518099	C	8.3	10.3	0.048	1.27 (1.00-1.62)	8.3	10.0	0.12	1.23 (0.95-1.59)	8.3	11.0	0.05	1.39 (0.99-1.93)	7.0	9.1	0.11	1.29 (0.94-1.75)
<i>TMCO1</i>	rs2814471	C	12.0	13.3	0.27	1.11 (0.93-1.32)	12.0	12.4	0.80	1.03 (0.85-1.24)	12.0	15.9	0.019	1.37 (1.05-1.77)	12.5	13.4	0.76	1.04 (0.81-1.34)
<i>CAV1/CAV2</i>	rs8940	C	81.4	79.1	0.051	0.86 (0.74-1.00)	81.4	79.2	0.08	0.86 (0.73-1.02)	81.4	78.8	0.15	0.84 (0.66-1.06)	82.3	79.4	0.10	0.83 (0.67-1.04)
<i>CAV1/CAV2</i>	rs1052990	A	61.2	58.0	0.029	0.87 (0.77-0.99)	61.2	58.2	0.06	0.88 (0.77-1.00)	61.2	57.2	0.08	0.85 (0.70-1.02)	61.3	57.8	0.11	0.87 (0.73-1.03)
<i>CAV1/CAV2</i>	rs6466578	C	19.6	18.1	0.23	0.91 (0.78-1.06)	19.6	18.7	0.52	0.95 (0.80-1.12)	19.6	16.3	0.08	0.80 (0.62-1.03)	21.4	18.8	0.19	0.86 (0.70-1.07)
<i>CAV1/CAV2</i>	rs3919515	C	38.4	37.3	0.41	0.95 (0.84-1.08)	38.4	37.3	0.44	0.95 (0.83-1.09)	38.4	37.2	0.59	0.95 (0.78-1.15)	37.4	36.2	0.56	0.95 (0.79-1.13)
<i>CAV1/CAV2</i>	rs10227696	A	18.7	20.5	0.13	1.13 (0.97-1.31)	18.7	20.2	0.20	1.11 (0.94-1.32)	18.7	21.1	0.18	1.17 (0.93-1.49)	17.3	20.3	0.09	1.21 (0.97-1.51)

Genetic Association Results for CAV1/CAV2 and CDKN2B-AS1																						
Locus	SNP ID	Allele	CAV1/CAV2 Association						CDKN2B-AS1 Association						Cross-Locus Interaction							
			Effect Size	SE	P-Value	OR	95% CI	Effect Size	SE	P-Value	OR	95% CI	Effect Size	SE	P-Value	OR	95% CI					
CAV1/CAV2	rs4236601	A	36.2	39.5	0.020	1.16	(1.02-1.31)	36.2	39.2	0.050	1.14	(1.00-1.31)	36.2	40.7	0.05	1.21	(1.00-1.47)	37.6	41.7	0.06	1.19	(0.99-1.42)
CAV1/CAV2	rs917664	A	48.7	49.1	0.72	1.02	(0.91-1.16)	48.7	49.1	0.75	1.02	(0.90-1.16)	48.7	49.3	0.79	1.03	(0.85-1.25)	51.4	51.5	0.98	1.00	(0.84-1.19)
CAV1/CAV2	rs3779512	A	66.5	67.6	0.43	1.05	(0.93-1.20)	66.5	68.0	0.28	1.08	(0.94-1.24)	66.5	66.3	0.90	0.99	(0.81-1.21)	71.5	72.4	0.74	1.03	(0.86-1.24)
CAV1/CAV2	rs3807986	C	55.8	55.8	0.97	1.00	(0.88-1.13)	55.8	55.9	0.93	1.01	(0.88-1.15)	55.8	55.4	0.84	0.98	(0.81-1.19)	68.1	63.5	0.015	0.80	(0.66-0.96)
CAV1/CAV2	rs3807989	C	34.2	34.4	0.97	1.00	(0.88-1.13)	34.2	33.7	0.56	0.96	(0.84-1.10)	34.2	36.7	0.28	1.12	(0.92-1.36)	29.5	27.5	0.35	0.91	(0.76-1.10)
CAV1/CAV2	rs3779514	A	23.8	24.2	0.69	1.03	(0.89-1.19)	23.8	24.8	0.41	1.07	(0.92-1.24)	23.8	22.4	0.47	0.92	(0.73-1.16)	27.9	27.9	0.84	0.98	(0.80-1.20)
CAV1/CAV2	rs3815412	A	61.4	62.5	0.51	1.04	(0.92-1.18)	61.4	62.4	0.63	1.03	(0.90-1.18)	61.4	62.8	0.54	1.06	(0.88-1.29)	62.7	58.5	0.03	0.82	(0.69-0.98)
CAV1/CAV2	rs8713	A	70.7	70.9	0.85	1.01	(0.89-1.16)	70.7	70.8	0.89	1.01	(0.87-1.17)	70.7	71.2	0.79	1.03	(0.83-1.27)	70.9	67.0	0.04	0.82	(0.68-0.99)
Chr8q22	rs284489	C	63.2	62.3	0.69	0.98	(0.86-1.10)	63.2	62.6	0.92	0.99	(0.87-1.13)	63.2	61.2	0.44	0.93	(0.77-1.12)	71.6	72.2	0.66	1.04	(0.86-1.27)
CDKN2B-AS1	rs2069422	G	9.8	9.8	0.96	1.01	(0.82-1.23)	9.8	9.5	0.86	0.98	(0.79-1.22)	9.8	10.6	0.57	1.09	(0.80-1.49)	9.8	9.2	0.75	0.95	(0.71-1.28)
CDKN2B-AS1	rs7049105	A	29.6	26.0	0.009	0.84	(0.73-0.96)	29.6	25.9	0.013	0.83	(0.72-0.96)	29.6	26.3	0.12	0.85	(0.69-1.05)	25.0	25.5	0.75	1.03	(0.85-1.25)
CDKN2B-AS1	rs2151280	A	30.9	33.1	0.19	1.11	(0.95-1.29)	30.9	32.5	0.38	1.08	(0.91-1.27)	30.9	34.5	0.11	1.19	(0.96-1.48)	28.5	26.4	0.25	0.89	(0.73-1.08)
CDKN2B-AS1	rs7851706	C	87.9	89.0	0.26	1.11	(0.92-1.34)	87.9	89.1	0.24	1.13	(0.92-1.38)	87.9	88.5	0.66	1.07	(0.80-1.43)	84.9	82.1	0.06	0.80	(0.64-1.01)
CDKN2B-AS1	rs10120688	A	40.9	45.6	0.002	1.21	(1.07-1.37)	40.9	44.9	0.012	1.18	(1.04-1.35)	40.9	47.7	0.004	1.32	(1.09-1.60)	39.5	36.1	0.10	0.86	(0.72-1.03)
CDKN2B-AS1	rs16905597	A	12.2	9.9	0.010	0.78	(0.64-0.94)	12.2	9.5	0.006	0.74	(0.60-0.92)	12.2	11.0	0.38	0.88	(0.66-1.18)	15.1	16.1	0.57	1.07	(0.85-1.36)
CDKN2B-AS1	rs16905599	C	77.8	75.2	0.04	0.86	(0.75-1.00)	77.8	74.9	0.04	0.85	(0.73-0.99)	77.8	76.0	0.33	0.90	(0.72-1.12)	73.6	75.7	0.28	1.12	(0.92-1.36)

Genetic Association Analysis Results for CDKN2B-AS1																		
Locus	SNP ID	Allele	Group 1 (n=100)				Group 2 (n=100)				Group 3 (n=100)				Group 4 (n=100)			
			Mean	SD	OR	95% CI	Mean	SD	OR	95% CI	Mean	SD	OR	95% CI	Mean	SD	OR	95% CI
CDKN2B-AS1	rs16923583	A	16.0	15.3	0.47	0.94 (0.80-1.11)	16.0	15.3	0.44	0.93 (0.78-1.11)	16.0	15.5	0.71	0.95 (0.73-1.24)	20.1	20.2	0.94	1.01 (0.81-1.25)
CDKN2B-AS1	rs1547705	A	75.8	77.0	0.43	1.07 (0.91-1.27)	75.8	77.4	0.33	1.10 (0.91-1.31)	75.8	76.1	0.97	1.01 (0.79-1.28)	72.1	72.2	0.89	1.01 (0.84-1.23)
CDKN2B-AS1	rs1537370	C	32.5	29.7	0.06	0.88 (0.77-1.00)	32.5	30.0	0.11	0.89 (0.77-1.03)	32.5	28.5	0.09	0.84 (0.68-1.03)	25.2	27.8	0.24	1.12 (0.93-1.36)
CDKN2B-AS1	rs10738607	C	24.2	22.7	0.32	0.92 (0.78-1.09)	24.2	21.9	0.16	0.88 (0.73-1.05)	24.2	24.5	0.82	1.03 (0.81-1.30)	19.0	18.8	0.95	0.99 (0.80-1.23)
CDKN2B-AS1	rs10965235	A	45.8	48.7	0.06	1.13 (1.00-1.27)	45.8	49.4	0.03	1.16 (1.01-1.32)	45.8	46.6	0.70	1.04 (0.86-1.25)	57.3	55.8	0.43	0.93 (0.79-1.11)
CDKN2B-AS1	rs4990722	G	84.6	85.3	0.55	1.05 (0.89-1.25)	84.6	85.0	0.65	1.04 (0.87-1.25)	84.6	86.2	0.41	1.12 (0.85-1.47)	81.5	80.9	0.79	0.97 (0.79-1.20)
CDKN2B-AS1	rs17761446	G	5.7	4.6	0.08	0.79 (0.60-1.03)	5.7	4.4	0.05	0.74 (0.55-1.00)	5.7	5.4	0.76	0.94 (0.63-1.41)	5.2	5.4	0.86	1.04 (0.70-1.53)
CDKN2B-AS1	rs1333049	C	25.7	23.5	0.10	0.89 (0.78-1.02)	25.7	23.0	0.07	0.87 (0.75-1.01)	25.7	25.2	0.78	0.97 (0.78-1.20)	18.5	19.0	0.68	1.05 (0.84-1.31)
CDKN2B-AS1	rs1333050	C	79.9	81.1	0.37	1.07 (0.92-1.24)	79.9	81.1	0.43	1.07 (0.91-1.26)	79.9	81.1	0.53	1.08 (0.85-1.36)	89.6	91.6	0.10	1.28 (0.95-1.73)
CDKN2B-AS1	rs10811658	A	43.0	46.8	0.04	1.17 (1.01-1.35)	43.0	46.5	0.07	1.16 (0.99-1.35)	43.0	47.6	0.08	1.21 (0.98-1.49)	43.8	45.5	0.48	1.07 (0.90-1.27)
CDKN2B-AS1	rs12347779	C	93.2	93.3	0.97	1.00 (0.78-1.27)	93.2	93.4	0.89	1.02 (0.79-1.32)	93.2	92.9	0.73	0.94 (0.65-1.35)	94.1	92.8	0.28	0.82 (0.57-1.18)
CDKN2B-AS1	rs10965245	A	18.6	15.5	0.006	0.80 (0.68-0.94)	18.6	14.5	0.0005	0.73 (0.61-0.87)	18.6	18.6	0.97	1.00 (0.78-1.27)	19.6	21.2	0.38	1.10 (0.89-1.35)
CDKN2B-AS1	rs2383208	A	82.3	81.0	0.24	0.91 (0.78-1.06)	82.3	81.4	0.42	0.94 (0.79-1.10)	82.3	79.8	0.18	0.85 (0.67-1.08)	80.8	82.1	0.47	1.09 (0.87-1.35)
CDKN2B-AS1	rs1063192	C	7.7	6.4	0.15	0.85 (0.67-1.06)	7.7	6.8	0.39	0.90 (0.70-1.15)	7.7	5.2	0.06	0.68 (0.46-1.01)	0	0.2	0.98	N/A
CDKN2B-AS1	rs4977756	C	35.3	33.0	0.16	0.91 (0.81-1.04)	35.3	33.9	0.41	0.95 (0.83-1.08)	35.3	30.4	0.04	0.82 (0.67-1.00)	34.6	36.3	0.44	1.07 (0.90-1.29)
CDKN2B-AS1	rs10116277	G	10.2	9.9	0.88	0.99 (0.81-1.20)	10.2	10.2	0.89	1.02 (0.82-1.26)	10.2	9.0	0.43	0.88 (0.64-1.21)	0.6	1.0	0.23	1.82 (0.68-4.85)

<i>CDKN2B-AS1</i>	rs4977574	A	80.0	80.9	0.48	1.05 (0.91-1.22)	80.0	81.2	0.41	1.07 (0.91-1.26)	80.0	79.9	0.99	1.00 (0.80-1.26)	87.1	88.1	0.48	1.10 (0.85-1.41)
<i>SIX1/SIX6</i>	rs2350890	C	57.3	58.9	0.31	1.07 (0.94-1.20)	57.3	58.7	0.42	1.06 (0.93-1.21)	57.3	59.6	0.36	1.09 (0.90-1.32)	57.6	58.7	0.65	1.04 (0.87-1.24)
<i>SIX1/SIX6</i>	rs4901977	A	58.1	58.3	0.99	1.00 (0.88-1.13)	58.1	58.0	0.79	0.98 (0.86-1.12)	58.1	59.2	0.67	1.04 (0.86-1.26)	63.3	65.9	0.28	1.10 (0.92-1.32)
<i>SIX1/SIX6</i>	rs8012339	A	82.2	81.8	0.56	0.95 (0.82-1.12)	82.2	81.4	0.31	0.92 (0.77-1.09)	82.2	83.3	0.64	1.06 (0.83-1.36)	78.3	77.8	0.69	0.96 (0.78-1.17)
<i>SIX1/SIX6</i>	rs1266416	C	53.5	52.4	0.50	0.96 (0.85-1.08)	53.5	53.0	0.74	0.98 (0.86-1.12)	53.5	50.7	0.24	0.90 (0.74-1.08)	44.5	47.8	0.14	1.14 (0.96-1.35)
<i>SIX1/SIX6</i>	rs3759688	A	22.0	22.1	0.88	1.01 (0.86-1.20)	22.0	21.9	0.97	1.00 (0.83-1.20)	22.0	22.6	0.63	1.06 (0.83-1.35)	29.4	28.6	0.86	0.98 (0.82-1.18)
<i>SIX1/SIX6</i>	rs11849906	G	7.3	6.8	0.43	0.91 (0.72-1.15)	7.3	7.7	0.77	1.04 (0.81-1.32)	7.3	3.9	0.006	0.53 (0.34-0.83)	8.4	10.1	0.18	1.23 (0.91-1.67)
<i>SIX1/SIX6</i>	rs10148202	A	15.8	14.3	0.13	0.88 (0.74-1.04)	15.8	14.5	0.18	0.88 (0.74-1.06)	15.8	13.9	0.24	0.85 (0.65-1.12)	17.0	17.3	0.72	1.04 (0.84-1.30)
<i>SIX1/SIX6</i>	rs7156317	A	65.5	65.9	0.73	1.02 (0.90-1.16)	65.5	66.2	0.61	1.04 (0.90-1.19)	65.5	65.0	0.87	0.98 (0.81-1.20)	58.0	59.7	0.52	1.06 (0.89-1.26)
<i>SIX1/SIX6</i>	rs7146104	A	3.7	4.4	0.17	1.24 (0.91-1.68)	3.7	4.3	0.23	1.22 (0.88-1.69)	3.7	4.7	0.25	1.32 (0.82-2.11)	6.8	6.5	0.70	0.93 (0.66-1.32)
<i>SIX1/SIX6</i>	rs10483727	C	12.4	11.9	0.67	0.96 (0.78-1.18)	12.4	11.9	0.97	0.99 (0.77-1.28)	12.4	11.8	0.66	0.92 (0.64-1.32)	1.2	1.4	0.76	1.13 (0.52-2.44)
<i>SIX1/SIX6</i>	rs33912345	A	12.5	11.2	0.25	0.88 (0.71-1.10)	12.5	11.1	0.91	0.99 (0.77-1.27)	12.5	11.6	0.57	0.90 (0.62-1.30)	1.1	1.1	0.93	0.96 (0.42-2.23)

SNP: single nucleotide polymorphism; POAG: primary open-angle glaucoma; ICAARE-Glaucoma: International Consortium of African Ancestry REsearch in Glaucoma; HPG: high pressure glaucoma; NPG: normal pressure glaucoma; AA: African American; FU: Allele frequency in controls; FA: allele frequency in POAG cases; P: p value from the logistic regression using additive model with the justification of age and gender; OR: odds ratio with 95% confidence interval in the parenthesis.